Aligos therapeutics presents positive clinical data at hep-dart 2023 from phase 1 studies in hbv (alg-000184) and nash (alg-055009)

South san francisco, calif., dec. 07, 2023 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (cam-e), alg-000184, and its thyroid hormone receptor-beta (thr-Β) drug candidate, alg-055009, at the hep-dart 2023 meeting, held in cabo san lucas, mexico, from december 3 – 7, 2023. the presentations can be found on the “scientific presentations & conferences” section of the aligos website (www.aligos.com).
ALGS Ratings Summary
ALGS Quant Ranking